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1. Introduction 
Of all the gynecologic cancers, ovarian malignancy represents the greatest clinical challenge 
because it is difficult for early detection, difficult to cure, and it has the highest fatality to 
case ratio of all the gynecologic malignancies. Many studies have been tried to find a novel 
strategy on early detection of ovarian cancer. Ultimately, successful screening in 
asymptomatic women could increase cure rate and prolong survival among patients who 
have to live with ovarian cancer. 
 
 
*Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. 
GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 
[Internet]. 
Lyon, France: International Agency for Research on Cancer; 2010. Available from: 
http://globocan.iarc.fr, accessed on day/month/year. 
Fig. 1. Estimated age-standardised incidence rate per 100,000 women-year of ovarian cancer, 
all ages. 
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2. Epidemiology and impact  
Higher than two hundred thousand women were diagnosed ovarian cancer in 2008 
worldwide(Ferlay, Shin et al. 2010). As a result, more than one hundred and forty thousand 
women accounting for more than fifty percent fatality to case ratio died in this year. Major 
incidences are in Northern America and Europe. In Asia, higher trend of incidence grows 
significantly. Unfortunately, ovarian cancer remains mysterious for early detection and cure. 
Morbidity and mortality from ovarian cancer have been major burdens from the past to the 
present.  
 
 
Region   
Ovarian cancer Cervical cancer Uterine cancer 
New cases Death  New cases Death  New cases Death  
World* 224,747 140,163 530,232 275,008 288,387 73,854 
US** 21,990 15,460 12,710 4,290 46,470 8,120 
Thailand*** 1,384 - 6,954 - 745 - 
*Ferlay, Shin et al. 2010 
**American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011.  
***Attasara P, Srivatanakul, P, Sriplung, H. cancer incidence in Thailand. In: Khuhaprema T, 
Srivatanakul P, Attasara P, Sriplung H, Wiangnon S, Sumitsawan Y, editor. Cancer in Thailand 2001-
2003 vol.V. 1st ed.  Bangkok: Bangkok Medical Publisher. 2010: 3-76. 
Table 1. Number of new cases and deaths from ovarian, cervical and uterine cancer in a 
year. 
2.1 The incidence and prevalence of ovarian cancer including the stage distribution  
World age-specific incidence rate of ovarian cancer was 6.3 per 100,000 women with a 
cumulative risk 0-74 year-old of 0.7 in 2008 (Ferlay, Shin et al. 2010).  It does not seem to 
significant lower from the year 2002. The distant and regional stage distributions are higher 
than localized ovarian cancer in both developed and developing countries as shown in table 
2. Overall five year survival rate in the SEER database is 45.9%(SEER). 
 
 
Ovarian cancer 
distribution 
US* Thailand** 
Percent  of 
cases 
5 year 
survival (%) 
Percent  of 
cases 
5 year  
survival (%) 
Localized  15 94 26 90 
Regional  23 73 39 80 
Distant  62 28 35 15-25 
* American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011. 
**modified from Wilailak S. Epidemiologic report of gynecologic cancer in Thailand. J Gynecol 
Oncol. 2009;20: 81–83. 
Table 2. The ovarian cancer distribution and percent of five-year survival. 
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2.2 The sequelae and impact of ovarian cancer 
Eventually, ovarian cancer impacts on patients’ survival and their quality of life. Suffering 
from gut obstruction and malnutrition, renal failure, liver failure, respiratory failure, severe 
chronic pain, infection and sepsis are expected during lifetime and at the end of life in 
women diagnosed with ovarian cancer. Impacts of ovarian cancer are direct from cancer and 
metastases and indirect from treatments and complications. 
Direct sequelae from cancer and metastases 
- Primary tumor: intractable pain 
- Secondary tumor: Brain, Bone, Lung, Liver, KUB system, GI system, lymph nodes 
Indirect sequelae from treatments and complications. 
- Surgery: hemorrhage, internal organ injury, gut obstruction. 
- Chemotherapy: Leukopenia, thrombocytopenia, sepsis, renal failure, cardiotoxicity, 
hypersensitivity reaction 
- Molecular therapy: hypertension, bowel perforation. 
3. Challenges of ovarian cancer 
Challenges toward early ovarian cancer diagnosis could increase cure rate, prolong survival 
and delay suffering from cancer and decreased interventive complications.  
3.1 Pre-Cancer lesion has not yet been identified 
Ovarian cancer pathogenesis has been hypothesized, but it and also pre-cancerous lesion 
have not yet been identified.  
3.2 Most cases are diagnosed in advanced stage 
Asymptomatic women with intra-abdominal concealing of ovarian cancer are most likely 
having late ovarian cancer diagnosis. Eighty-five percent of patients with ovarian cancer are 
diagnosed when the cancer cells already metastases out of the ovary to the whole abdomen. 
Survival and prognosis directly relate to extent of disease. Asymptomatic or nonspecific 
symptoms always found in women with early ovarian cancer.  
3.3 Symptoms are non-specific 
Ninety percent of patients with ovarian cancer had non-specific symptoms which mostly 
were misdiagnosed and delayed proper treatments for some periods.  
3.4 Difficulty in palpation by either patients or physicians 
Women could not feel abdominal mass or even any abnormalities before the mass enlarged 
to beyond her pubic symphysis. Physicians could palpate any mass of ovarian cancer during 
pelvic examination.  
3.5 Result of the treatment is poor in advanced stage 
Contemporary standard primary treatment is surgery and adjuvant combined 
chemotherapy for early stages cancer. In advanced cancer, initially exploratory laparotomy 
with biopsy followed by palliative chemotherapy and/or secondary cytoreductive surgery 
or neo-adjuvant chemotherapy followed by primary cytoreductive surgery is decided 
depending on individualized patient. The most reliable prognosis depends on the residual 
tumor after every attempted surgery.  
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3.6 The present tumor markers are non-specific 
Tumor markers are non-specific. Currently, CA125 is widely used as the most promising 
tool along with contemporary standard primary treatment. CA125 is a tumor-associated 
antigen which is detected in 80-85 percent of epithelial ovarian cancer. Only fifty percent of 
patients with FIGO stage I and 60% of patients with FIGO stage II has shown an increased 
CA125 level. Moreover, CA125 test has low specificity among women with reproductive 
age, pregnancy and benign diseases including myoma uteri, endometriosis, and pelvic 
infection. Data suggest that combined CA125 and transvaginal ultrasonography improved 
specificity for ovarian cancer screening. 
4. Screening target population 
Currently, there are no effective screening methods that could decrease mortality from 
ovarian cancer. They are evidences for ovarian cancer screening in both general and high 
risk population. 
4.1 General population 
Mass screening in asymptomatic and general risk population seems to be ineffective and 
associated with increased rates of surgery and patient anxiety(Fung, Bryson et al. 2004). Two 
large studies in Europe and Northern America (Menon, Gentry-Maharaj et al. 2009; Buys, 
Partridge et al. 2011) have shown currently data. The prostate, lung, colorectal and ovarian 
(PLCO) cancer screening randomized controlled trial was conducted in the United States. 
Asymptomatic women aged 55-74 years who had no previous diagnosis of lung, colorectal or 
ovarian cancer were recruited between 1993-2001. Thirty-nine thousand one hundred and five 
participants received annual screening with transvaginal ultrasounds for four years and 
CA125 blood tests for six years. On comparison, Thirty-nine thousand one hundred and eleven 
participants received usual medical care. The positive predictive value was only 23.5%. Sixty 
percent of invasive cancers would not have been detected by the screening. Only 21 percent of 
the participants, who were detected cancer by the screening, were stage I/II.  It was shown 
that women who were screened for ovarian cancer with annual transvaginal ultrasound and 
CA125 blood test had not reduced ovarian cancer mortality. In addition, the screening 
increased invasive medical procedures and associated harms (Buys, Partridge et al. 2011). 
The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was 
studied between 2001-2005 (Menon, Gentry-Maharaj et al. 2009). Post-menopausal women 
aged 50—74 years were randomly assigned to no treatment (control; n=101 359); annual 
CA125 screening with transvaginal ultrasound scan as a second-line test (multimodal 
screening [MMS]; n=50 640); or annual screening with transvaginal ultrasound (USS; 
n=50 639) alone in a 2:1:1 ratio (Menon, Gentry-Maharaj et al. 2009).  
Forty-two women with the annual CA125 screening and transvaginal ultrasound scan and 
45 women with annual transvaginal ultrasound were detected primary ovarian and tubal 
cancers including 28 borderline tumors (eight MMS, 20 USS). 28 (16 MMS, 12 USS) of 58 
(48·3%) of the invasive cancers were stage I/II, with no difference in stage distribution 
between the groups. For primary invasive epithelial ovarian and tubal cancers, the 
sensitivity, specificity, and positive-predictive values were 89·5%, 99·8%, and 35·1% for 
MMS, and 75·0%, 98·2%, and 2·8% for USS, respectively. Specificity was higher in the 
annual CA125 screening with transvaginal ultrasound scan than in the annual screening 
with transvaginal ultrasound alone group, resulting in lower rates of repeat testing and 
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surgery. The screening strategies might be feasible. However, the results of ongoing 
screening are awaited to determine the effect of the screening on mortality from ovarian 
cancer (Menon, Gentry-Maharaj et al. 2009). 
4.2 Increased-risk population 
Prevalence of ovarian cancer is higher in high risk population. Positive family history of 
specific cancers, menopause and having adnexal mass are higher probabilities for ovarian 
cancer.  Screening benefits should be more pronounced and encourage. In addition, 
screening by gynecologic oncologists is feasible and cost effective.  
4.2.1 Menopause 
Senescence is significantly caused genetic aberration inducing cancer. Postmenopause are 
high risk for ovarian cancer (Hensley, Robson et al. 2003).  
4.2.2 Positive family history 
Women with certain family histories have higher risks of ovarian cancer than general 
population. Ten percent of women with epithelial ovarian cancer have mutations in the 
BRCA1 and BRCA2 genes with located on chromosome 17 and 13 respectively. Lynch II 
syndrome is a less common genetic cause of ovarian cancer and endometrial cancer, which 
is known as the hereditary nonpolyposis colorectal cancer syndrome (HNPCC syndrome). 
There is a very limited benefit, of screening even in high-risk women with BRCA1 and 
BRCA2 mutation carriers (Hermsen, Olivier et al. 2007; Woodward, Sleightholme et al. 
2007). In addition, annual gynecological screening is unlikely to reduce mortality in women 
with BRCA1 and BRCA2 mutation carriers (Hogg and Friedlander 2004; Hermsen, Olivier et 
al. 2007). 
4.2.3 Having adnexal mass 
Malignant ovarian masses are pathological diagnosed. Occasionally, it is possible to 
differentiate benign from malignant tumors on the basis of history and physical examination 
findings. 
5. General characteristics of a good cancer screening 
Screening for ovarian cancer is a method for secondary prevention by early detection 
followed with definite treatment. Efficacy screening depends on 5 factors including 
incidence of disease, effective early treatment, available cost effectiveness method and 
adequate population target. Impact of ovarian cancer burden and surgically and adjuvant 
chemotherapeutic effective early treatments are significantly propagated the development of 
a good ovarian cancer screening. There are general characteristics to consider. 
a. High sensitivity, specificity and predictive value 
Accuracy for screening is necessary. Ideally, a good cancer screening for ovarian cancer could 
decrease mortality rate significantly. As this result, it could detect ovarian cancer among 
women who have the cancer. It could discrete non-ovarian cancer women among truly non-
ovarian cancer women. Moreover, the test should be accurate on the results of the tests, it 
means that truly non-ovarian cancer women would be among negative tests’ women and truly 
asymptomatic women with ovarian cancer would be among positive tests’ women. More than 
75 percent sensitivity and more than 99 percent specificity of the most effective test is required 
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to achieve a positive predictive value of 10 percent(Moore, MacLaughlan et al. 2010). These 
mean ten operations of each case of ovarian cancer detected. 
b. Safe 
Safety set as a priority for mass screening in asymptomatic women. 
c. Simple 
Simple method screening which is easy and noninvasive is suitable to coverage the target 
population.  
d. Inexpensive 
Cost of the screening should be paid on attention other than its effectiveness. Cost could be 
one of the obstacles to be refused and ignore from the target population.  
6. The aim of ovarian cancer screening is an attempt to detect early-stage 
asymptomatic individuals 
6.1 Tools for ovarian cancer screening 
Beyond pelvic examination, various tools are proposed including tumor markers, 
ultrasonography and abdominal imaging. 
6.2 Tumor markers 
The most extensively evaluated and available tumor marker currently is Cancer Antigen 125 
(CA125). It has been firstly introduced as OC125 since 1981(Bast, Feeney et al. 1981). Up to 
eighty percent of patients with advanced epithelial ovarian cancer had high CA125 levels 
during diagnosis. However, only 50 percent of patients at early staged ovarian cancer were 
found higher levels than serum thresholds. Low specificity and variable levels of CA125 
resulted in low accurate for screening. Many benign gynecologic and medical conditions 
compromised the specificity. However, CA125 remains valuable for follow up in women 
with epithelial ovarian cancer who have ever had high CA125 level. 
6.3 Imaging 
6.3.1 Ultrasonography 
Utrasonographic results could discriminate patients with ovarian malignancy including 
bilaterality, large cystic structure, any solid lesions (as shown in picture 1), and papillary 
vegetation on the cyst wall or ascites. Accuracy of ultrasonography is still low for detecting 
ovarian cancer. 
6.3.2 Computerized tomography (CT), Magnetic resonance imaging (MRI) 
High false positive rate for detecting ovarian cancer using imaging technology have been 
reports. Individualized patients who should have benefits from the imaging should be 
judged by their physicians. 
7. Single modality of screening or multiple modalities 
7.1 Single/multiple tumor markers 
Various types of tumor markers have been study both early staged and late staged of 
ovarian cancer (Table 3)(Rein, Gupta et al. 2011). High serum levels of HE4, Osteopontin, 
Mesothelin, B7-H4, Prostatin and VEGF were found in both early staged and late staged 
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ovarian cancer. A number of tumor markers were detected only in late staged of cancer as 
shown in table 3.  
 
 
Picture 1. Transabdominal ultrasonography of 44 year-old, single woman with palpable 
pelvic mass has shown mixed solid cystic mass sized 11.8 cm. Postoperative pathologic 
diagnosed clear cell adenocarcinoma of ovary, FIGO stage IC. 
 
Tumor markers* 
Early staged 
Advanced  
and late-staged 
HE4 HE4 
Osteopontin Osteopontin 
Mesothelin  Mesothelin  
B7-H4 B7-H4 
Prostasin Prostasin 
VEGF VEGF 
IGFBP-3 IGFBP-3 
RASSF1A RASSF1A 
BRCA1 BRCA1 
LPA LPA 
IL-6, IL-8 Haptoglobin 
Eosinophil-derived neurotoxin and COOH-osteopontin fragments M-CSF 
OVX1 Sat2-Chr1, Satα 
APOA1 and transthyretin MCJ 
 P53 
*modified from Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers 
for detection and monitoring of ovarian cancer. J Oncol 2011;2011: 475983. (Rein, Gupta et al. 
2011)  
Table 3. The tumor markers detect during early staged and late staged of ovarian cancer. 
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Human epididymis protein 4 (HE4) is elevated in ovarian cancer, especially endometrioid 
adenocarcinoma and serous cystadenocarcinoma (Scholler, Crawford et al. 2006). 
Osteopontin is a glycoprotein and secreted from vascular endothelial cells and osteoblasts. It 
has an ability to inhibit apoptosis and correlates with metastasis(Denhardt and Noda 1998). 
Mesothelin expresses on the surface of mesothelial cells. It is overexpressed in ovarian 
cancer, mesotheliomas and pancreatic cancer (Hassan, Remaley et al. 2006). 
B7-H4 over expressed in T-cells and ovarian cancer including serous cystadenocarcinoma, 
endometrioid adenocarcinoma and clear cell carcinoma. Its levels were elevated 45% of 
patients with early stage ovarian cancer (Simon, Zhuo et al. 2006). 
Hepatoglobin originated from the liver. It has been shown expression in ascetic fluid and 
serum of patients with ovarian cancer. Higher levels of hepatoglobin have been associated 
with poor prognosis(Zhao, Annamalai et al. 2007). The levels also decreased during 
chemotherapy.  
CA125 is only promising tumor marker currently, but it is low specificity. In combination 
with CA125, other serum tumor markers have been evaluated to improve the accuracy with 
some limitations (Visintin, Feng et al. 2008; Amonkar, Bertenshaw et al. 2009; Nosov, Su et 
al. 2009). The study in 2008 evaluated various combinations of 9 markers including CA125, 
HE4, SMRP, CA72-4, Osteopontin, ERBB2, Inhibin, Activin, and EGFR. Dual marker 
combination of CA125 and HE4 had a greater sensitivity than either marker alone (Moore, 
Brown et al. 2008). However, the dual markers are limited in detecting epithelial ovarian 
cancer of mucinous cell type. Human epididymis protein4 (HE4) has equivalent sensitivities 
to CA125 for detecting malignancy in women with pelvic masses (Shah, Lowe et al. 2009).  
In addition, HE4 has greater specificity in premenopausal women due to it does not 
influence by benign gynecologic conditions. Contrary, another study has shown that in 
combination of HE4 and CA125 test was no benefit in clinical practice(Jacob, Meier et al. 
2011). HE4 is going on studies for ovarian cancer screening. 
7.2 The risk of malignancy index (RMI) 
The risk of malignancy index (RMI) was introduced for discriminating ovarian cancer from 
other ovarian mass (Jacobs, Oram et al. 1990). The RMI score is calculated from 
menstruation status, ultrasonographic result and CA125 level. RMI cut-off level of 200 has 
85% sensitivity and 97% specificity to identify ovarian cancer. 
RMI indices followed by Histoscanning study, a novel computer aided diagnostic tool, were 
assessed in 199 women with adnexa masses. A cutoff RMI value of 250 resulted in 74% 
sensitivity and 86% specificity. The RMI indices  with cutoff values between 105-2100 
followed by Histoscanning study improved diagnostic accuracy in women with adnexal 
masses with 88% sensitivity and 95% specificity (Vaes, Manchanda et al. 2011). 
7.3 Risk of malignancy algorithm (ROMA) 
The risk of malignancy algorithm (ROMA) is a scoring system in combination of CA125 and 
HE4 which shows excellent diagnostic performance for the detection of epithelial ovarian 
cancer in post-menopausal women presenting with pelvic mass (Montagnana, Danese et al. 
2011).  
Using ROMA, 389 women with pelvic mass were measured serum levels of HE4 and CA125 
preoperatively. A cutoff of 12.5% for pre-menopausal patients had 67.5% sensitivity and 
87.9% specificity. A cutoff of 14.4% for postmenopausal patients had 90.8% sensitivity and 
66.3% specificity. However, HE4 and ROMA did not increase the detection of ovarian cancer 
comparing to CA125 alone (Van Gorp, Cadron et al. 2011).  
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On comparison, the dual markers using HE4 and CA125, calculated a ROMA value were 
evaluated preoperatively (Moore, Jabre-Raughley et al. 2010). This study used the following 
predictive probability algorithm (ROMA): 
Premenopausal Predictive index (PI) = -12+2.38*LN (HE4) +0.0626*LN (CA125) 
Postmenopausal Predictive index (PI)  = -8.09+1.04*LN (HE4) +0.732*LN (CA125) 
Predicted probability       = exp (PI)/ [1+exp (PI)] 
The following equation was used to calculate RMI: 
    RMI = U X M X serum CA125 
  Where   U = 0 for imaging score of 0 
    U = 1 for imaging score of 1 
    U = 3 for imaging score of 2-5 
    M = 1 if premenopausal 
    M = 3 if postmenopausal 
It shows significant higher sensitivity for detecting epithelial ovarian cancer than RMI as 
shown in figure 5 (Moore, Jabre-Raughley et al. 2010). 
 
Group  
Sensitivity  
(%) 
Positive predictive value 
(%) 
Negative predictive 
value (%) 
ROMA RMI 
Pretest 
P value 
ROMA RMI ROMA RMI 
Benign vs. 
EOC and 
LMP 
89.0 80.7 0.0113 62.3 59.7 93.6 89.3 
Benign vs. 
EOC stage 
I-IV 
94.3 84.6 0.0029 59.8 56.8 97.1 92.5 
Benign vs. 
EOC stage 
I-II 
85.3 64.7 0.0000 27.1 21.8 97.9 95.1 
Benign vs. 
EOC stage 
III-IV 
98.8 93.0 0.0350 52.1 50.3 99.6 97.5 
*modified from Moore. Comparison of a novel multiple marker assay versus the RMI. Am J 
Obstet Gynecol 2010. 
Table 4. The sensitivity, positive predictive value and negative predictive value between 
Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) of 
benign tumor and epithelial ovarian cancer (EOC) stage I-IV at a set specificity of 75%. 
LMP= low malignant potential. 
Receiver operating characteristic (ROC) analysis of individual tumor markers and their 
combinations were evaluated and summarized(Jacob, Meier et al. 2011). HE4 performed best 
83.3% sensitivity and 84.6% specificity. Whereas ROMA were 85.4% sensitivity and 85.6% 
specificity (Table 4).  
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Tumor markers and their 
combinations 
Borderline tumors and cancer group versus  
non-malignant group 
AUC Sensitivity (%) Specificity (%) 
HE4 0.89 83.3 84.6 
CA125 0.87 60.4 91.3 
CA125*HE4 0.90 70.8 94.2 
ROMA 0.90 85.4 85.6 
RMIHE4 0.93 79.1 86.5 
RMICA125 0.95 66.7 97.1 
RMICA125*HE4 0.95 75.0 98.1 
*modified from Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and 
CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011;121(3): 487-91. 
(Jacob, Meier et al. 2011) 
Table 5. The AUC, sensitivity and specificity of individual tumor markers and their 
combinations between borderline tumors and cancer group versus non-malignant group. 
8. Economic evaluation: Cost effectiveness analysis 
During economic crisis around the world, the cost effectiveness should be evaluated. It is 
estimated the cost-effectiveness of different screening strategies using a stochastic 
simulation model (Skates and Singer 1991). On prediction, a multimodel strategy would cost 
51,000 US dollars per year of life saved. Therefore, it would be potentially cost-effective for 
ovarian cancer screening (Sfakianos and Havrilesky 2011).  
9. Conclusion and recommendations 
In conclusion, screening for ovarian cancer would be emerged as a promising strategy to 
increase cure rate, prolong survival and decrease morbidities in the future. Further 
evaluations for ovarian cancer screening and early detection should be encouraged. 
Understanding preclinical ovarian cancer and development of novel effective strategy could 
lead for early detection, ultimately it will decrease incidence and mortality from ovarian 
cancer. 
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